EUVIMEDEUVIMED entdecken
Kommentar

Andexanet alfa and heparin resistance in cardiac surgery: Experiences and risks associated with the reversal of direct oral anticoagulants

Daniel-Sebastian Dohle iD, Philipp Pfeiffer iD, Chris Probst, Hendrik Treede iD

European Journal of Cardio-Thoracic Surgery · 01.06.2023 · 63 (6)

DOI: 10.1093/ejcts/ezad189 ↗

Kurz gefasst

Kommentar in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 05.05.2023. Verfasst von Daniel-Sebastian Dohle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Johannes-Gutenberg University, Mainz, Germany. Hauptthemen laut MEDLINE: Acute Aortic Syndrome, Cardiac Surgical Procedures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In their case report ‘Andexanet alfa in acute aortic syndrome: first UK experience’, Al-Attar et al. describe their experiences with Andexanet alfa (AA) in the context of emergency surgeries for type A aortic dissections [1]. In 3 patients, AA was used, with 2 patients receiving it after cardiopulmonary bypass (CPB) and 1 patient receiving it pre-hospital, thereby before CPB. While the procedure was complication free and hemostasis was ensured in the 2 patients who received AA post-CPB, achieving suitable ACT despite repetitive heparin administrations in the patient with pre-hospital AA administration proved difficult. Eventually, clots were even found in the venous reservoir of the heart–lung machine. Direct oral anticoagulants (DOACs) prevent and treat thrombosis and embolism. They have fewer interactions with food and drugs and require fewer blood tests compared to vitamin K antagonists. Dabigatran, the first DOAC and a direct thrombin inhibitor, was approved in Europe in 2008 and the USA in 2010. Direct factor Xa inhibitors rivaroxaban and apixaban were approved in Europe in 2008 and 2011, respectively, and in the USA in 2011 and 2012. Additional DOACs like edoxaban and betrixaban have since become available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Aortic SyndromeCardiac Surgical ProceduresHumansHeparinAnticoagulantsUnited KingdomRecombinant ProteinsFactor Xa

Stichwörter der Autor:innen

Andexanet alfadirect oral anticoagulantsheart-lung machineheparin resistance

Substanzen

HeparinAnticoagulantsPRT064445Recombinant ProteinsFactor Xa

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Johannes-Gutenberg University, Mainz, Germany.

ORCID-Profile: Daniel-Sebastian Dohle, Philipp Pfeiffer, Hendrik Treede

Zitieren

APA

Dohle, D. S., Pfeiffer, P., Probst, C., & Treede, H. (2023). Andexanet alfa and heparin resistance in cardiac surgery: Experiences and risks associated with the reversal of direct oral anticoagulants. European Journal of Cardio-Thoracic Surgery, 63(6). https://doi.org/10.1093/ejcts/ezad189

Vancouver

Dohle DS, Pfeiffer P, Probst C, Treede H. Andexanet alfa and heparin resistance in cardiac surgery: Experiences and risks associated with the reversal of direct oral anticoagulants. European Journal of Cardio-Thoracic Surgery. 2023;63(6). doi:10.1093/ejcts/ezad189

BibTeX
@article{Dohle2023,
  author = {Dohle, Daniel-Sebastian and Pfeiffer, Philipp and Probst, Chris and Treede, Hendrik},
  title = {Andexanet alfa and heparin resistance in cardiac surgery: Experiences and risks associated with the reversal of direct oral anticoagulants},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2023},
  volume = {63},
  number = {6},
  doi = {10.1093/ejcts/ezad189}
}
Kostenlos starten →